FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Price & Overview
NASDAQ:FBIOP • US34960Q2084
Current stock price
The current stock price of FBIOP is 12.87 USD. Today FBIOP is down by -3.26%. In the past month the price increased by 15.84%. In the past year, price increased by 93.83%.
FBIOP Key Statistics
- Market Cap
- 399.485M
- P/E
- N/A
- Fwd P/E
- 1,261.76
- EPS (TTM)
- -1.62
- Dividend Yield
- N/A
FBIOP Stock Performance
FBIOP Stock Chart
FBIOP Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to FBIOP. When comparing the yearly performance of all stocks, FBIOP is one of the better performing stocks in the market, outperforming 96.08% of all stocks.
FBIOP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FBIOP. FBIOP may be in some trouble as it scores bad on both profitability and health.
FBIOP Earnings
On November 14, 2025 FBIOP reported an EPS of 0.11 and a revenue of 17.63M. The company beat EPS expectations (125.68% surprise) and missed revenue expectations (-17.76% surprise).
FBIOP Forecast & Estimates
8 analysts have analysed FBIOP and the average price target is 42.99 USD. This implies a price increase of 234% is expected in the next year compared to the current price of 12.87.
For the next year, analysts expect an EPS growth of 109.83% and a revenue growth 24.62% for FBIOP
FBIOP Groups
Sector & Classification
FBIOP Financial Highlights
Over the last trailing twelve months FBIOP reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 57.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.94% | ||
| ROE | -9.55% | ||
| Debt/Equity | 0.86 |
FBIOP Ownership
FBIOP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FBIOP
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Company Info
IPO: 2011-11-17
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA US
Employees: 101
Phone: 17816524500
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ
Can you describe the business of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
What is the current price of FBIOP stock?
The current stock price of FBIOP is 12.87 USD. The price decreased by -3.26% in the last trading session.
Does FBIOP stock pay dividends?
FBIOP does not pay a dividend.
What is the ChartMill technical and fundamental rating of FBIOP stock?
FBIOP has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for FBIOP stock?
8 analysts have analysed FBIOP and the average price target is 42.99 USD. This implies a price increase of 234% is expected in the next year compared to the current price of 12.87.
Can you provide the market cap for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a market capitalization of 399.48M USD. This makes FBIOP a Small Cap stock.
Who owns FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?
You can find the ownership structure of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) on the Ownership tab.